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Sensitization in the neuroscience and pharmacology literatures is defined as progressive increase
in the size of a response over repeated presentations of a stimulus. Types of sensitization include
stimulant drug-induced time-dependent sensitization (TDS), an animal model related to substance
abuse, and limbic kindling, an animal model for temporal lobe epilepsy. Neural sensitization
(primarily nonconvulsive or subconvulsive) to the adverse properties of substances has been
hypothesized to underlie the initiation and subsequent elicitation of heightened sensitivity to low
levels of environmental chemicals. A corollary of the sensitization model is that individuals with
illness from low-level chemicals are among the more sensitizable members of the population.
The Working Group on Sensitization and Kindling identified two primary goals for a research
approach to this problem: to perform controlled experiments to determine whether or not
sensitization to low-level chemical exposures occurs in multiple chemical sensitivity (MCS)
patients; and to use animal preparations for kindling and TDS as nonhomologous models for the
initiation and elicitation of MCS. Environ Health Perspect 105(Suppl 2):539-547 (1997)
Key words: sensitization, kindling, mesolimbic, human, animal, time factors, low-level
exposures, psychophysiology
Background
Sensitization is the progressive increase in Antelman (2,3), involves sensitization by
the size ofa response over repeated presen- the simple passage of time between initial
tations ofa stimulus (1). Time-dependent and later reexposures to a stimulus. Thus,
sensitization (TDS), a term suggested by intermittency is an important time-related
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feature ofstimuli that initiate sensitization
as opposed to continuous exposures that ini-
tiate tolerance (4). Pharmacologic agents,
direct electrical stimulation, and physical
and psychological stressors can all initiate
or elicit the amplified responses in TDS
(2,5,6,7). Sensitization can interact with
tolerance and with conditioning (8-10),
but each of these processes can be distin-
guished from the other by proper experi-
mental design (8-10). The mechanisms of
sensitization are not fully understood but
may involve persistent changes in neuro-
transmitters, receptors, and basic neural
cellular functions (5,6). Sensitization of
immune function can occur during TDS
protocols (11), but neural rather than clas-
sical immunological changes appear to
mediate TDS ofneurobehavioral functions
(2,6,12). For example, various investiga-
tors have blocked drug-induced sensitiza-
tion in the central nervous system using
excitatory amino acid antagonists (13),
nitric oxide synthase inhibitors (14), pro-
tein synthesis inhibitors (15), or delta-opi-
oid receptor antagonists (16). In TDS, the
subcortical, dopaminergic mesolimbic
pathways also may be involved (5,6). A
special type of neural sensitization is kin-
dling, in which periodic repeated electrical
or chemical stimulation of brain limbic
structures such as the olfactory bulb, amyg-
dala, and areas ofthe hippocampus leads to
permanent susceptibility to convulsions
not seen upon initial stimulation (17-22).
Because most persons with multiple
chemical sensitivity (MCS) do not have
clinical seizure disorders, kindling per se is
not the most apt model for their condition
(7). However, nonconvulsive TDS, sub-
convulsive kindling and/or related neural
sensitization processes (7,18,20-23) could
provide an explanation for a puzzling fea-
ture ofMCS, i.e., susceptibility to low levels
ofenvironmental chemicals that according
to classical toxicological dose-response rela-
tionships should not occur (24). Convergent
lines of evidence point to this possibility.
First, a subset, though not all, of MCS
patients has been found to have increased
lifetime histories or comorbid histories of
certain psychiatric disorders, specifically
major depression, anxiety disorders, and
somatoform disorders (25-29). Researchers
in biological psychiatry have proposed for
many years that the recurrent, long-term
course ofthese conditions follows the pat-
tern of a sensitized response in that pro-
gressively less severe life stress or eventually
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no stress at all is required to trigger later
episodes ofillness (12,30). Still others have
reported increased histories of childhood
abuse in certain MCS patients (31). Early
abuse may trigger increased rates ofpost-
traumatic stress disorder (PTSD) (32,33).
PTSD is a condition ofpersistent hyperre-
activity to salient stimuli and other envi-
ronmental stimuli (e.g., startle to noise) for
which TDS is a leading model (2,34).
Rather than assume that MCS is merely a
misattribution of psychiatric symptoms
from those conditions, an alternative view
would be that the psychiatric findings and
the MCS are both the result ofan increased
susceptibility to sensitization (7,22).
The second line ofevidence that could
provide an explanation for some patients'
susceptibility to low levels ofenvironmen-
tal chemicals is that other characteristics of
TDS and MCS overlap (3,5,7,22,35-37).
For example, females are more susceptible
to both TDS and MCS (38). Both pro-
cesses can be initiated by a wide range of
chemically unrelated agents (3). Agents of
different types can cross-sensitize with one
another (2,3,5). Elicited responses can
proceed in a bidirectional manner (39,40).
The amplified responses can occur in mul-
tiple different bodily systems (2,3,5,17).
Individuals sensitized through TDS and
those with MCS can appear no different
from the normal population in their
responses to a given agent (a) at an initial
but not later exposure (41); (b) at later
exposures if insufficient time has passed
since the last sensitizing exposure (6,42)
(i.e., sensitization may not yet have occurred
or is obscured by tolerance); (c) at later
exposures ifencountered under novel condi-
tions different from those under which the
original sensitization developed (8,43). An
important implication ofthe latter points is
that it will be essential to perform multiple,
not one, exposure sessions separated in time
to test the sensitization model for MCS
(7,22,36). That is, it is necessary to initiate
and elicit sensitization within the same
experiment (42). Otherwise, negative find-
ings could be explained as a lack ofpreexist-
ing sensitization or as a suppression of a
truly sensitized response by tolerance or by
the novelty ofthe experimental situation at
the time ofasingle test session.
Experimental Design-
Human Studies
ParticipantSelection
Demographic variables important to MCS
research include gender, age, education,
and occupational/chemical exposure histo-
ries. The Working Group on Sensitization
and Kindling concluded that research in
MCS needs a generally accepted structured
interview based upon common patterns of
patient symptoms. Such an interview
would help characterize the nosology of
MCS and facilitate comparison of results
between studies. It is feasible and reason-
able to borrow from the precedents of
mainstream psychiatry that generated the
standardized Diagnostic and Statistical
Manual (DSM)(44) and its associated
Structured Clinical Interviewfor DSM
Diagnosis (SCID)(45). These systematic
tools for psychiatric diagnosis rely on
patient self-reports ofparticular patterns of
symptoms; determination of clinician
agreement over etiological factors is not
required for most diagnoses except for
those related to specific drugs ofabuse or
organic causes such as a recognized medical
condition. Ifand when generally accepted
objective markers for MCS become avail-
able, specific test parameters can be incor-
porated into the overall case definition.
This does not imply that MCS is or is not
a psychiatric disorder. Rather, use ofa phe-
nomenologically based interview would
capture the state ofknowledge in the field
at that time in a practical way so as to
advance understanding ofthe problem.
Chronicity of illness would be impor-
tant to establish, e.g., 6 months or longer,
to eliminate persons with self-limited acute
or subacute toxic reactions to accidental
poisonings. The MCS interview items also
should draw upon the descriptive scientific
data beginning to emerge from surveys of
patients (46) and the clinicians who evalu-
ate them (47-51). For example, the num-
ber of incitant chemicals and severity of
illness attributed to chemicals, regardless of
the specific symptoms, may help distin-
guish MCS from overlapping syndromes
such as chronic fatigue or fibromyalgia
(47). Another important subtyping ques-
tion might ask for self-identification of a
defined initiating chemical exposure,
induding age at onset versus no clear onset
date or event (51). Marked changes in
lifestyle attributed to chemical sensitivity
(26) are also distinguishing features ofclin-
ical MCS, including disability or change in
occupation, personal hygiene products,
places frequented or traveled to, home
structure, and furnishings (46). Queries
about specific symptoms might include the
most frequent MCS complaints, e.g., feel-
ings ofunreality, memory difficulties, dizzi-
ness or lightheadedness, problems focusing
eyes, muscle aches, tingling in fingers
and/or toes, tiredness, irritability (46).
Clinically, most MCS patients report addi-
tional intolerances to common foods and
various medications (46,52).
One potentially important set ofsub-
typing questions would be about past
and/or current history ofcertain psychiatric
disorders (51). For those items, the MCS
interview might borrow the screening ques-
tions for past and current depression, anxi-
ety disorders, and somatization disorder
from the psychiatric SCID or other vali-
dated instruments [e.g., somatization screen
(53); Minnesota Multiphasic Personality
Inventory (MMPI) (54); Symptom
Checklist 90, revised (SCL-90-R) (55)].
For instance, one could have dementia
with or without comorbid depression (44).
Similarly, available data indicate that one
could have MCS with orwithout comorbid
depression or anxiety disorders (49-51).
Preliminary electroencephalographic studies
by Bell et al. (56) indicate that the electro-
physiological activation patterns ofindivid-
uals with both chemical intolerance and
depression differ from those of persons
with only one or the other condition or
neither. Thus, it may be essential to recruit
subjects systematically who have or do not
have specific features. Subject screening
should include validated self-report and
observer-rated measures ofdepression and
anxiety, with specific cut-off scores for
inclusion and exclusion criteria. Self-report
measures could include instruments such as
the Beck Depression Inventory (57) and the
Spielberger State-Trait Anxiety Inventory
(58); observer-rated measures could include
the Hamilton Depression and Hamilton
Anxiety Scales (59). By the same token,
control/comparison groups, e.g., depressives
or panic disorder patients, would have to be
screened specifically to eliminate those
with high levels ofchemical intolerance.
Preclinical or clinically mild chemical intol-
erance with minimal associated lifestyle
changes is common in nonindustrial sam-
ples (60-67). However, previous controlled
studies generally have not screened for
chemical intolerance, thereby adding a
major design flaw into comparisons of
MCS patient groups with other groups
such as medically ill patients or even some
normal persons. A central tenet ofexperi-
mental design is to select groups that dif-
fer on the key independent measure under
consideration, e.g., degree ofself-reported
chemical odor intolerance.
Because of the lack of previous human
studies in this area using specific outcome
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measures with chemical exposures, it is dif-
ficult to predict the appropriate group sam-
ple sizes to ensure adequate statistical power
with certainty. However, sample sizes in the
several studies that have demonstrated sig-
nificant sensitization or failure ofhabitua-
tion of autonomic variables in human
subjects have fallen in the range of9 to 25
subjects per group (42,68,69). The ability
to detect significant group differences in
these between-group studies with these
small samples suggests large estimated effect
sizes. Similarly, animal studies ofchemical
sensitization with behavioral end points
have used 9 to 32 animals per group
(5,20,70). A between-subjects design in
human studies could risk Type II error
from insufficient sample size and too low
power to detect medium- or small-sized
effects. Nonetheless, the high likelihood of
carryover effects from one exposure condi-
tion to another in a within-subjects design
favors using a between-subjects approach.
Ifwithin-subjects designs are used, a coun-
terbalanced order ofexposure conditions in
separate subgroups of each group, e.g.,
MCS and controls, would assist in clarify-
ing any such asymmetric transfer ofeffects
(71). It will be necessary to restrict the
number ofoutcome measures in any given
protocol to limit confounding of results
of one outcome measure by a preceding
outcome measure (72).
An additional consideration for experi-
mental design is that of stimulus range
effects (73). The range ofstimuli or the
range ofresponses used by the subjects may
affect their responses (73). That is, sensiti-
zation studies within subjects would risk
confounding by range effects ifa given sub-
ject were to undergo more than one experi-
mental condition. This problem again
favors the use ofseparate groups for each
concentration, stressor, and time factor.
The nature ofsensitization studies requires
use ofrepeated sessions with the same out-
come measure(s) in the same subjects, but
the experimental condition (i.e., chemical
vs sham exposures) and the timing ofexpo-
sures must differ among subgroups ofeach
group. Taken together, these issues point to
the need for a large number of separate
groups in human or animal sensitization
studies to be certain ofthe source ofa given
finding. For example, Antelman et al. (74)
used nine separate groups rather than the
same group of animals (n = 6-10 per
group) to evaluate the effects on mesolim-
bic dopamine status ofpretreatment with a
range ofdifferent intensity environmental
stressors (home cage, clean cage, dirty cage,
black box) interacting with a range ofdrug
treatment conditions (no injection, saline
injection alone, or 0.2 mg/kg haloperidol in
saline given at three different time lags after
the pretreatment: none, 2 hr, or 2 weeks).
They also used entirely separate groups of
animals to confirm the stressfulness ofeach
ofthe pretreatment conditions with gluco-
corticoid measurements. It also may be nec-
essary to consider similar separate studies
and between-groups methodology in
human sensitization studies (71-73).
Experimental Conditions
Among many potential issues in the design
ofhuman MCS/sensitization studies are the
following: state ofadaptation or deadapta-
tion ofsubjects (24); route ofsensitizing
and test exposures (e.g., oral, inhalation,
dermal); environmental context (novel ver-
sus familiar). For the first issue, Ashford et
al. (75) and Miller (76) have presented a
systematic case for the need for an environ-
mentally controlled medical unit where
human subjects could be cleared ofpossible
masking, adaptation, and/or pharmaco-
logical cross-tolerance to multiple inhaled
chemicals. The sensitization working group
agreed that one design for protocols to ini-
tiate and test for sensitization in MCS
patients could involve the same sensitization
procedures but compare outcomes under
conditions ofmasking and unmasking.
Related to the second issue, route of
sensitization, laboratory sensitization in ani-
mals has been initiated primarily by injec-
tion with drugs or pesticides (3-6,19,20)
and inhalation with solvents such as tolu-
ene (21,70). In human studies, oral alco-
hol ingestion has been used successfully to
initiate and demonstrate autonomic ner-
vous system sensitization of nonalcoholics
without first withdrawing them from alco-
hol outside the laboratory (42). The work-
ing group discussed the possibility of
separate human studies involving different
types of agents and routes ofadministra-
tion, e.g., oral ingestion of a drug-such as
methylphenidate or inhalation exposure to
a solvent such as toluene. The advantage of
testing for drug sensitization is the greater
potential control over cross-sensitizing or
cross-tolerant exposures outside the labora-
tory. From an ethical perspective, using a
stimulant drug such as methylphenidate
versus a placebo in humans would be a
clinically appropriate trial. Current stan-
dards ofpractice in psychiatry indicate that
low-dose stimulants may particularly bene-
fit persons with low energy or depression
related to medical conditions (77).
A test of stimulant sensitization in
MCS patients and controls also would
facilitate understanding of the question of
the presence or absence ofheightened gen-
eral sensitizability in MCS patients, even
though it would not directly address the
involvement of specific environmental
chemicals. Alternatively, the group consid-
ered other agents such as opiate drugs, sub-
stance P, or alcohol for possible tests of
TDS. For example, Antelman (3) noted
that human sensitization ofP-endorphin to
interleukin-2 has been shown in clinical
populations (non-MCS) (78). Bell et al.
(79) also have evidence that specific foods
might induce sensitization ofO-endorphin
in nonclinical chemically intolerant elderly.
Another important advantage of using
drugs to test for TDS would be to evaluate
the capacity ofselected outcome measures
under consideration for chemical exposure
studies to exhibit sensitization. Repeated
drug administrations would permit refine-
ment of these outcome measures during
administration of better studied agents at
doses with known effects compared to pos-
sibly arbitrary selections of test chemicals
and concentrations for initial chemical
exposure studies.
In the case ofinhaled volatile exposures
in the laboratory as sensitizing events, one
approach could mimic elements ofthe dose
selection procedures used in Molhave et al
(80). Different subgroups could receive var-
ious doses, e.g., low doses: subolfactory lev-
els ofa given substance (e.g., toluene) or
volatile mixture (e.g., Molhave volatile
organic compound mixture found in indoor
air) in an exposure test chamber; moderate
doses: detectable levels of a substance or
mixture similar to those measured in sick
buildings; high doses: detectable levels but
below Occupational Safety and Health
Administration (OSHA) standards for an
industrial workplace. The duration ofdos-
ing would be important. Antelman (2)
emphasized that briefexposures to a sensi-
tizing agent may be more effective at initi-
ating just sensitization and not tolerance,
whereas prolonged exposures may tend to
induce both sensitization and tolerance.
Thus, studies could compare exposure
durations ofseveral minutes, 1 hr, or 6 to
8 hours at a time.
With regard to the third issue in the
design ofhuman sensitization studies, envi-
ronmental context, Bell et al. (36) have
extensively discussed the contextual points
involved in sensitization research. These are
relevant to ethical concerns to avoid persis-
tent injury to subjects' health outside the
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laboratory setting. One way to approach
these concerns would be to initiate human
subjects in a context-dependent rather than
independent manner (9,42,81,82). That is,
the protocol for initiating sensitization
would require that the physical setting (e.g.,
distinctive laboratory appearance, color of
walls, etc.), procedures, and time ofday be
identical for both sensitization and testing
sessions. Varying the context in which sen-
sitization occurs could induce context-
independent sensitization such as may
relate to MCS patients' heightened chemi-
cal reactivity in a wide range of environ-
ments different from that ofthe originally
identified exposure event. In contrast, the
proposed laboratory procedures would
require that the context remain the same
throughout the study in order that the risk
ofsubjects later reacting adversely be con-
fined to reexposures during any return vis-
its to the laboratory situation and not to
other situations in their everyday lives.
Thus, while context-dependent designs
would help address ethical concerns for
human studies, these same issues make it
imperative that full testing ofthe sensitiza-
tion hypothesis for MCS employ animal
models to permit initiation and assessment
ofcontext-independent sensitization, i.e.,
administer the agent in various cages
and/or rooms throughout the study.
The basic protocol for initiating and
testing for context-dependent sensitization
in human subjects would then involve at
least two and preferably three or more lab-
oratory sessions well spaced in time. The
time interval between sessions for initiating
TDS could range from 1 to 14 days.
Testing immediately after a daily protocol
in animals often does not reveal the sensiti-
zation (6). Past research suggests that it
would then be necessary to wait at least
several days, preferably 7 to 14 days, after
the final sensitizing exposure to test for
development of a sensitized response.
While context-dependent designs by defin-
ition invoke elements ofclassical condi-
tioning to the environment, it is still
possible to design studies to differentiate
sensitization from conditioning. For exam-
ple, drawing from similar animal research
(9), it would be possible to establish the
development of an amplified response in
humans to a given substance with a sensiti-
zation protocol, then repeatedly reexpose
them to the same setting and procedures
with sham exposures (e.g., arrowroot
starch-filled capsules for drug placebo or
filtered airstreams for inhalation route)
until the amplified response returns to
baseline, i.e., extinguishes. Then another
test exposure with the active agent is con-
ducted to see if the amplified response
returns immediately. Ifso, then sensitiza-
tion and conditioning factors have been
separated; that is, the sensitized response is
still present (elicitable) even though the
conditioned, context-dependent compo-
nent ofthe response is not (9,10).
Another variation of the contextual
design that demonstrates the context-
dependence would be to initiate laboratory
sensitization to a given substance in a par-
ticular room ofthe laboratory and then test
for TDS by reexposing halfofeach group
to the same substance in the original expo-
sure room and half of each group to the
same substance in a distinctively different
exposure room. Because novelty is expected
to dampen the size ofa sensitized response
in context-dependent TDS (8-10), it is
predicted that the sensitized group(s) would
show a lesser response to the substance in
the new room compared with that in the
old room. However, retesting in the old
room should reinstate the amplified
response promptly. Various between-groups
and within-groups crossover designs (e.g.,
ABABAB) counterbalanced for order oftest
room type (new or old) could be utilized
[(71-73) however, on unwanted within-
subjects effects]. Another possible strategy
for addressing the ability of novelty to
dampen elicitation ofsensitization responses
would be to habituate subjects to the labora-
tory setting and procedures for several ses-
sions without chemical or drug exposures
before beginning the sensitization process.
DependentVariables
One ofthe least discussed but most impor-
tant methodological issues in MCS research
is the selection ofoutcome measures. Many
investigators have elected relatively insensi-
tive designs involving subjects' dichoto-
mous guesses about the presence or absence
of a chemical and/or subtle increases in
subjective symptoms. While this approach
may be especially important in the clinical
situation and should be included in any
human study, the Sensitization Working
Group considers it necessary but not suffi-
cient for the research situation. Dependent
variables that would add objectivity and
sensitivity to experimental design would
include neurophysiological (e.g., olfactory-
evoked potentials, cognitive event-related
potentials [ERPs] such as P300, quantita-
tive electroencephalography [EEG], and
polysomnography) (83-87); neuroimaging
(e.g., functional MRI); autonomic (e.g.,
pupil response, heart rate, blood pressure,
respiratory, pulmonary function tests)
(68,69); cognitive (e.g., continuous perfor-
mance tests, divided attention tests, informa-
tion-processing tests) (88-90); behavioral
(e.g., Profile ofMood States [POMS] scale,
anxiety sensitivity index) (79,91); and
motor activity (e.g., physical activity moni-
tors, facial electromyography [EMG] for
positive and negative affect, acoustic startle
responses) (42,64).
There are several advantages to most of
the above measures. First, most ofthe vari-
ables can detect subtle and/or rapid changes
in function as well as failure to habituate
upon repeated sampling (68). Second, all
variables except neuroimaging are relatively
inexpensive and noninvasive to obtain
repeatedly once the equipment has been
purchased. These measures have been and
currently are in use in scientific studies of
human subjects with cognitive, affective, or
somatic symptoms similar to those reported
in MCS, e.g., dementias, depressions,
PTSD, chronic pain, migraine headache,
irritable bowel. Thus, the available research
literature using those same measures would
offer information on the specificity ofany
findings in MCS compared with findings
for better characterized disorders.
Finally, testing the sensitization hypo-
thesis in human subjects involves impor-
tant methodological considerations. Design
issues that pertain to TDS studies can dif-
fer from those used when testing other
hypotheses for MCS. For example, the
seemingly reasonable approach ofpretest-
ing with open challenges (75) ofpossible
active and placebo substances to determine
current reactivity or nonreactivity in MCS
is not possible from a TDS perspective.
Even in animal studies, prior experience
with a stimulus changes a given individ-
ual's responsivity to later reexperiences if
the individual is sensitizable (2). Thus,
lack ofinitial reactivity to a particular sub-
stance does not necessarily predict lack of
subsequent reactivity (2,3,5,6,41). Indeed,
many different agents and stimuli evoke no
difference in the first session ofTDS studies
between animals that will eventually sensi-
tize and those that will not. A placebo at
the beginning ofan experiment could turn
into an active agent in a sensitizable subject
by the end oftesting
For this reason, most animal TDS
studies utilize between-group rather than
within-group designs (2,5,6). For example,
one of several control groups proceeds
through the experiment with no exposures
to the test agent. Another control group
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receives the test agent only at the final test-
ing session. In comparison, the experimental
group(s) receive the test agent repeatedly at
each sensitizing session and at the final test-
ing session. In addition to designs using dif-
ferent initiating exposures, another design
strategy is to compare groups ofanimals
predicted to exhibit individual differences in
sensitizability. Such groups would include
different genetic strains (92), females versus
males (93,94), or hyperreactivity versus
hyporeactivity to novelty (41). That is, half
the animals are predicted to be maximally,
and halfto be minimally, sensitizable. For
*human studies, selection ofcontrol groups
to compare with MCS patients might mean
ensuring that such groups lack potential
for sensitizability, e.g., no family histories
ofrecurrent affective disorders or substance
abuse (65), as well as no self-reported
chemical odor intolerance.
In summary, theworking group suggests
two primary experimental approaches, one
involving a shorter-term repeated measures
design, the other involving longitudinal fol-
low-up ofpersons who had experienced an
identifiable chemical exposure event. The
first study would compare MCS patients
with anyofvarious control groups for initia-
tion and elicitation ofsensitization to low-
level chemical exposures. The second study
would determine risk factors for developing
MCS by assessing persons who later develop
MCS and those who do not.
Experiment 1,Repeated
MeasuresStudy
The first study would test the hypothesis
that MCS patients are more susceptible to
initiation ofcontext-dependent sensitiza-
tion than control subjects. This short-term
between-subjects sensitization study (over a
period of 6 weeks, one session per week)
would involve three sessions ofhabituation
to the laboratory and procedures but with-
out chemical exposures followed by three
test sessions (active or placebo). Pilot
studies should include pretesting the sensi-
tivity ofproposed outcome measures to
sensitization in normals (who then would
not participate in any other part of the
research) to an agent such as methyl-
phenidate; and determination ofolfactory
thresholds in MCS patients and controls
(who then would not participate in any
other part ofthe research) for active chemi-
cal agents used in the study. For the primary
study, participants would include MCS
patients with and without depression and
nonchemically sensitive controls with and
without major depression. The study will
purposely oversample women to approxi-
mate the reported gender distribution
among MCS sufferers (24). In view ofthe
animal evidence that a high estrogen-to-
progesterone ratio might favor sensitization
in females (93) and that testosterone might
lessen sensitization in males (94), an
adjunctive exploratory measure for risk of
sensitization in this human study might be
blood levels ofestrogen and progesterone at
specified times in the menstrual cycle as well
as bloodlevels oftestosterone.
From the above list ofpossible depen-
dent variables, an initial selection might
include physiological measures considered
most likely to detect group differences, i.e.,
stabilometer (general motor activity level),
respiration, heart rate, pupil, EEG and
cognitive event-related potentials (auditory
odd-ball paradigm), and facial EMG (an
objective and sensitive correlate of mood
state). For mood changes and cognitive
dysfunction respectively, the POMS and
specific neuropsychological tests previously
found to show differences from those of
controls in studies ofchemically intolerant
or solvent-exposed persons (e.g., divided
attention, continuous performance test)
would be appropriate (85,89,95).
All participants would undergo initial
baseline sessions on filtered room air deliv-
ered by an olfactometer similar to that used
by Kobal and Hummel (83) to facilitate
habituation to the novelty ofthe laboratory
and procedures. For subsequent sessions in
this study, an olfactometer would deliver
brief exposures to filtered room air (the
placebo) and test chemicals (e.g., subolfac-
tory and supraolfactory threshold levels of
toluene in air stream) (below and above
threshold). Half the participants in each
group would get filtered room air during
the entire experiment and half of each
group would get the chemical (split-plot
design). The exposure would occur as
either intermittent bursts (1-min exposure,
3-min wait) or continuous exposures for at
least 10 to 15 min. Additional sessions
would occur at 1-, 2-, and 3-week intervals
at the same time ofday.
While studies designed to elicit acute
adverse reactions in MCS patients raise eth-
ical concerns, the need for systematic
understanding ofthis illness and its mecha-
nisms is pressing. Lack ofdata has severely
hampered research on possible preventive
and treatment interventions. At the present
stage ofknowledge about MCS, the poten-
tial benefits outweigh the risks. That is,
acute reactions in chemically sensitive indi-
viduals typically resolve within minutes to
hours after conclusion ofa low-level chemi-
cal exposure. Most patients do not experi-
ence life-threatening symptoms during such
reactions, and those with disorders such as
asthma or epilepsy can be screened out of
the studies. However, even in standard clin-
ical practice, diagnostic testing for condi-
tions with episodic rather than continuous
clinical manifestations, e.g., methacholine
challenge in asthma or hyperventilation
during EEG recording in epilepsy, often
involves deliberate provocation of acute
exacerbations as part of a workup. The
laboratory context-dependent design ofthe
present proposed experiments would mini-
mize the risk ofpersistent worsening ofa
patient's long-term course, as discussed
above. Thus, it is reasonable to proceed
with acute chemical exposure research in
MCS at this time. The emergence ofnew
data in the area may or may not necessitate
reassessment of the ethics of additional
challenge studies in the future.
Experiment2, LongitudinalStudy
In addition to acute studies, longitudinal
studies with repeated measures would per-
mit evaluation offluctuations over time in
MCS, which is inherently a chronic condi-
tion (48). As indicated above, studies of
sensitization require repeated measure
designs. Ethical concerns in human research
obviously preclude any experimental effort
to initiate MCS in healthy persons. Rather,
participant samples for a longitudinal study
would include individuals either with pre-
existing MCS or with a history ofan acute
identifiable toxicant exposure (cohort of
persons who proceed over time to develop
or not develop MCS). This approach takes
advantage of preexisting conditions in
affected persons, and involves repeated
evaluations of symptoms, mood, electro-
physiological and autonomic status, and
cognitive performance. The use of these
outcome measures does not appear to raise
any ethical concerns, as they would moni-
tor but not alter the course of MCS
patients' illnesses. Nonetheless, these mea-
sures might reveal evidence ofa sensitized
state in MCS patients [compare Morrow
and Steinhauer (68)]. In addition to
descriptive data on the course ofMCS, a
longitudinal study would test the hypothe-
sis that MCS patients but not healthy simi-
larly exposed individuals show maintenance
and/or progression of sensitization in
measures of nervous system dysfunction
over extended periods of time, following
induction by an initial toxic exposure or
other event.
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Periodic laboratory reevaluations would
permit assessment of progressive change
(e.g., worsening, improvement, plateau) or
persistence ofchange over extended blocks
of time [e.g., seven or eight times on an
every-6-months basis during a 5-year
study, compare Morrow and Steinhauer
(68)]. Monthly laboratory evaluations
would entail excessive subject burden and
risk; however, the working group recom-
mends monthly telephone follow-up data
collection. Outcome variables on which
the telephone component could focus
include a POMS, an individualized symp-
tom-rating scale for frequency and severity,
updates on medical/psychiatric diagnoses
and treatments, and a quality-of-life ques-
tionnaire. Six-month laboratory follow-
ups could include specific variables such as
cognitive, affective (POMS, MMPI), and
physiological (ERPs in response to the
challenge). If a component of the study
assessed MCS in its adapted versus non-
adapted state to obtain continuous phy-
siological recordings, an inpatient study in
an environmental medical unit would
be necessary.
Overall, this model encompasses both
the possibility of individual differences
between MCS patients and normal patients
in general sensitizability and cross-sensitiz-
ability to different agents and classes of
stimuli and the possibility ofdifferences
between chemical agents in their abilities
to initiate and elicit sensitization in persons
with equivalent degrees ofsensitizability.
Studies designed to evaluate each of these
areas may be needed to provide a complete
test ofthe model.
Animal Studies
Rationale
If a kindlinglike process or neural time-
dependent sensitization is a mechanism
that underlies MCS, direct olfactory stimu-
lation probably represents the most likely
route of exposure (21,96-98). Although
inhalation exposures through the lung
obviously occur simultaneously with olfac-
tory system stimulation, and although the
inhalation route may play some role in
modulation of neural sensitization, the
concentration ofinhaled chemicals reach-
ing the brain from nonolfactory routes of
administration probably is not sufficient
to cause the kinds of neural activation
necessary to support a kindlinglike process
(98). Accordingly, although bloodborne
chemical contaminants may contribute to
some systemic chemical kindlinglike
effect, if a neural sensitization process is
involved in the development ofMCS, it is
more probable that the process involves
the output from stimulation of the olfac-
tory apparatus (96-101).
Olfactory pathways, specifically the
olfactory bulbs, are particularly sensitive to
electrical and chemical kindling (21).
Additionally, the receptors in the olfactory
epithelium form a direct access pathway to
limbic structures in the central nervous sys-
tem. It is reasonable, therefore, to assume
that strong activation ofthe olfactory epi-
thelium cells can provide sufficient input
into CNS limbic circuits to induce sensiti-
zation. It probably is possible to design
studies that indirectly test this hypothesis
using human subjects, but the specific role
ofolfactory stimulation in the ontogeny of
MCS can be directly evaluated using stan-
dard neurophysiological assessments ofcen-
tral olfactory and limbic structures in
response to stimulation of the olfactory
epithelia oflaboratory animals (21).
Experimental Procedures
The following procedures test the hypothe-
sis that repeated olfactory exposures to
chemicals can modulate neurophysiological
activity in the olfactory-limbic axis or that
neurophysiological activity in the olfac-
tory-limbic axis can be modulated using
techniques such as footshock-induced
stress, partial limbic kindling, or psychos-
timulant sensitization, which have been
implicated in physiological or behavioral
sensitization.
Experiment 1. The most direct test of
an olfactory system-mediated sensitization
process involves the monitoring of olfac-
tory-limbic neural activity during and after
repeated stimulations of the olfactory
epithelium with compounds implicated in
the initiation ofMCS. Although it is prob-
able that CNS olfactory activity has been
assessed after chemical stimulation ofthe
olfactory epithelium, it is improbable that
structures other than the olfactory bulb
have been studied, and that the olfactory
bulb recording studies that have been
conducted have assessed long-term changes
in neural functioning after systematic
repetitive chemical stimulations.
Paradigm. Microelectrode bundles will
be chronically implanted into the olfactory
bulbs, the pyriform cortex, the hippocam-
pus, the entorhinal cortex, the amygdala,
the medial hypothalamus, or the ventral
tegmental area. The olfactory epithelium
will be stimulated with vapors from chemi-
cals believed to initiate MCS, vapors from
chemicals not usually reported to initiate
MCS, or distilled water vapor six times in a
2-hr testing session at equally spaced 20-
min intervals. Exposure procedures for
inhaled vapor generation will be adapted
from Wood et al. (102-103). Unit firing
patterns will be assessed from each of the
microelectrode bundles during stimulation
for a period of 15 min following cessation
of stimulation. Testing sessions will be
conducted daily for 15 days. In addition,
to test for changes that may occur after the
passage of time, animals will be tested 30
and/or 60 days later.
Experiment2. Genetic or other predis-
posing variables may account for an innate
predisposition for induction ofsensitization
in persons who present with symptoms of
MCS. Ifthis is true, it is possible that sensi-
tization arising from direct olfactory stimu-
lation may not specifically induce limbic
sensitivity in normal (i.e., nonsensitivity-
primed) rats. The following experiment tests
the hypothesis that exposures to initiating
chemicals can modulate neurophysiological
activity in the olfactory-limbic axis in rats
that have undergone experimental manipu-
lations previously demonstrated to result in
neural sensitization.
Paradigm. Rats will be implanted with
microelectrode bundles and groups ofani-
mals evaluated for baseline chemically
induced firing patterns using the same pro-
cedure as in Experiment 1. The animals
will be sensitized by one of the following
procedures: footshock stress-induced sen-
sitization; partial amygdala kindling; or
psychostimulant sensitization. Neural
responses to chemical olfactory stimula-
tion will be reassessed following induction
ofsensitization.
Experiment 3. It is possible that an
interaction exists between repeated olfac-
tory stimulation and other sensitization
induction processes in which sensitization
induced by some other physiological
process (e.g., stress) is exacerbated by prior
repeated olfactory stimulation. The follow-
ing experiments test the hypothesis that
repeated exposure to chemicals can alter
sensitization parameters in experimental
manipulations previously demonstrated to
result in neural sensitization.
Paradigm. Groups of rats will be
exposed to chemicals as in Experiment 1
over 15 trial days. Following the olfactory
stimulation procedure, the rats will be
sensitized by the procedures described in
Experiment 2. Latency or number oftrials
required to induce sensitization are then
compared.
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Conclusions
The Working Group on Sensitization and
Kindling agreed that a neural sensitization
hypothesis for initiation and elicitation of
MCS is testable in both human and animal
experiments. Both kinds of experiments
are essential to provide a full test of the
hypothesis and, in animal research, to per-
mit further elucidation ofunderlying mech-
anisms. The public health implications of
chemical intolerance or chemical sensitivity
are potentially extensive. A problem such as
chemical odor intolerance, reported at sub-
clinical degrees byat least 15% ofAmerican
nonindustrial populations, e.g., young
adults (61,64,65) and active community
elderly (62,63) as well as by 30% ofoffice
workers (67) and of a rural community-
based population (66), merits systematic
investigation ofits phenomenology, course,
and possible mechanisms.
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